Turtle Cameron's most recent trade in Spyre Therapeutics Inc. was a trade of 10,176 Common Stock done at an average price of $87.4 . Disclosure was reported to the exchange on July 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 87.44 per share. | 01 Jul 2026 | 10,176 | 587,364 (2%) | 0% | 87.4 | 889,789 | Common Stock |
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 88.12 per share. | 01 Jul 2026 | 4,234 | 583,130 (2%) | 0% | 88.1 | 373,100 | Common Stock |
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 88.91 per share. | 01 Jul 2026 | 590 | 582,540 (2%) | 0% | 88.9 | 52,457 | Common Stock |
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 70.50 per share. | 01 Jun 2026 | 8,149 | 600,834 (2%) | 0% | 70.5 | 574,505 | Common Stock |
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 69.40 per share. | 01 Jun 2026 | 3,557 | 608,983 (2%) | 0% | 69.4 | 246,856 | Common Stock |
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 71.38 per share. | 01 Jun 2026 | 3,294 | 597,540 (2%) | 0% | 71.4 | 235,126 | Common Stock |
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 69.54 per share. | 01 May 2026 | 5,300 | 622,240 (2%) | 0% | 69.5 | 368,562 | Common Stock |
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 70.77 per share. | 01 May 2026 | 3,600 | 618,640 (2%) | 0% | 70.8 | 254,772 | Common Stock |
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 73.14 per share. | 01 May 2026 | 3,100 | 614,540 (2%) | 0% | 73.1 | 226,734 | Common Stock |
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 74.23 per share. | 01 May 2026 | 1,700 | 612,840 (2%) | 0% | 74.2 | 126,191 | Common Stock |
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 71.76 per share. | 01 May 2026 | 1,000 | 617,640 (2%) | 0% | 71.8 | 71,760 | Common Stock |
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 74.96 per share. | 01 May 2026 | 300 | 612,540 (2%) | 0% | 75.0 | 22,488 | Common Stock |
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 49.20 per share. | 01 Apr 2026 | 12,344 | 630,196 (2%) | 0% | 49.2 | 607,325 | Common Stock |
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 49.92 per share. | 01 Apr 2026 | 2,656 | 627,540 (2%) | 0% | 49.9 | 132,588 | Common Stock |
| Galecto Inc | Cameron Turtle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2026 | 37,313 | 37,313 | - | - | Stock Option (right to buy) | |
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 42.49 per share. | 02 Mar 2026 | 9,100 | 642,540 (2%) | 0% | 42.5 | 386,659 | Common Stock |
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 41.73 per share. | 02 Mar 2026 | 5,900 | 651,640 (2%) | 0% | 41.7 | 246,207 | Common Stock |
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 32.87 per share. | 02 Feb 2026 | 14,043 | 657,540 (2%) | 0% | 32.9 | 461,593 | Common Stock |
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 31.82 per share. | 02 Feb 2026 | 957 | 671,583 (2%) | 0% | 31.8 | 30,452 | Common Stock |
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2026 | 528,000 | 528,000 | - | - | Stock Option (Right to Buy) | |
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 30.47 per share. | 02 Jan 2026 | 12,709 | 674,198 (2%) | 0% | 30.5 | 387,243 | Common Stock |
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 31.79 per share. | 02 Jan 2026 | 2,191 | 672,007 (2%) | 0% | 31.8 | 69,652 | Common Stock |
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 32.39 per share. | 02 Jan 2026 | 100 | 671,907 (2%) | 0% | 32.4 | 3,239 | Common Stock |
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 28.73 per share. | 01 Dec 2025 | 10,995 | 690,912 (2%) | 0% | 28.7 | 315,886 | Common Stock |
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 29.83 per share. | 01 Dec 2025 | 4,005 | 686,907 (2%) | 0% | 29.8 | 119,469 | Common Stock |
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 23.13 per share. | 03 Nov 2025 | 28,155 | 718,752 (2%) | 0% | 23.1 | 651,225 | Common Stock |
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 23.66 per share. | 03 Nov 2025 | 16,845 | 701,907 (2%) | 0% | 23.7 | 398,553 | Common Stock |
| Oruka Therapeutics Inc | Cameron Turtle | Director | 02 Jun 2025 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | ||
| Spyre Therapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 370,000 | 370,000 | - | - | Stock Option (Right to Buy) | |
| Spyre Therapeutics Inc | Turtle Cameron | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 9.82 per share. | 15 Feb 2024 | 400 | 746,907 (2%) | 0% | 9.8 | 3,928 | Common Stock |
| Aeglea BioTherapeutics Inc | Cameron Turtle | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 277,750 | 277,750 | - | - | Stock Option (Right to Buy) |